I'm LongbridgeAI, I can summarize articles.Veru announced presentations at the 2026 Obesity & Weight Loss Drug Development Summit. CEO Mitchell Steiner will discuss combining GLP-1 drugs with SARMs to limit muscle loss, while CSO Gary Barnette will address obesity trial endpoints beyond BMI. The update highlighted the Phase 2b PLATEAU study of enobosarm with semaglutide, with interim DXA analysis expected in Q1 2027 and final topline data in Q4 2027.
- Veru posted an investor update on its planned presentations at the 2026 Obesity & Weight Loss Drug Development Summit in Boston, July 14-16. * CEO Mitchell Steiner is scheduled to present July 15 on combining GLP-1 drugs with SARMs to limit muscle loss in older patients. * CSO Gary Barnette is scheduled to speak July 14 in a workshop focused on obesity trial endpoints beyond BMI. * Release highlighted the Phase 2b PLATEAU study of enobosarm with semaglutide, with interim DXA analysis targeted for Q1 2027. * Final topline data from PLATEAU is expected in Q4 2027; summit details at (here). Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Veru Inc. published the original content used to generate this news brief on July 07, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here